ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 282,69
0,14%
Dow Jones
43 297,03
0,91%
DAX
19 848,77
-0,34%
Brent Oil
73,575
0,40%
Bitcoin
95 723,29
-3,60%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Medicinova Inc (MNOV) Cours

Medicinova Inc

Medicinova Inc (MNOV)

NASDAQ
2,07
-0,05
(-2,36%)
Fermé 24 Décembre 10:00PM
Retardé de 15 minutes
2,07
0,00
( 0,00% )
Avant marché: 12:02PM
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
2,07
Prix Achat
2,07
Prix Vente
2,40
Volume échangé
-
0,00 Fourchette du Jour 0,00
1,12 Plage de 52 semaines 2,55
Cap du marché
101,526M
Clôture Veille
2,07
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume financier
-
VWAP
-
Volume moyen (3 m)
73 252
Actions en circulation
49 046 246
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-11,84
Bénéfice par action (BPA)
-0,17
Chiffre d'affairess
1M
Bénéfice net
-8,57M

À propos de Medicinova Inc

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's cu... MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. It has the acquisition and development of the small molecule therapeutics segments. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.medicinova.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Medicinova Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker MNOV. Le dernier cours de clôture d'Medicinova était de US$2,07. Au cours de la dernière année, les actions de Medicinova ont été négociées dans une fourchette de prix de US$ 1,12 à US$ 2,55.

Medicinova compte actuellement 49 046 246 actions en circulation. La capitalisation boursière d'Medicinova est de US$101,53 million. Medicinova a un ratio cours/bénéfice (ratio PE) de -11.84.

MNOV Dernières nouvelles

Plus de nouvelles

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

06 Décembre 2024
GlobeNewswire Inc.

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

LA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock...

19 Novembre 2024
GlobeNewswire Inc.

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

15 Novembre 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

13 Novembre 2024
Edgar (US Regulatory)

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...

12 Novembre 2024
GlobeNewswire Inc.

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

24 Octobre 2024
GlobeNewswire Inc.

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

LA JOLLA, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

30 Septembre 2024
GlobeNewswire Inc.

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

10 Septembre 2024
GlobeNewswire Inc.

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

LA JOLLA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

04 Septembre 2024
GlobeNewswire Inc.

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

30 Août 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.08-3.720930232562.152.23641.9482402.13450386CS
40.041.970443349752.032.481.9529162.22855615CS
120.084.020100502511.992.551.49732522.15256664CS
260.6343.751.442.551.12531811.96979322CS
520.6242.75862068971.452.551.12494681.7205933CS
156-0.72-25.80645161292.793.181.12518822.11306379CS
260-4.73-69.55882352946.813.251.122761946.38455996CS

MNOV - Frequently Asked Questions (FAQ)

What is the current Medicinova share price?
The current share price of Medicinova is US$ 2,07
How many Medicinova shares are in issue?
Medicinova has 49 046 246 shares in issue
What is the market cap of Medicinova?
The market capitalisation of Medicinova is USD 101,53M
What is the 1 year trading range for Medicinova share price?
Medicinova has traded in the range of US$ 1,12 to US$ 2,55 during the past year
What is the PE ratio of Medicinova?
The price to earnings ratio of Medicinova is -11,84
What is the cash to sales ratio of Medicinova?
The cash to sales ratio of Medicinova is 101,47
What is the reporting currency for Medicinova?
Medicinova reports financial results in USD
What is the latest annual turnover for Medicinova?
The latest annual turnover of Medicinova is USD 1M
What is the latest annual profit for Medicinova?
The latest annual profit of Medicinova is USD -8,57M
What is the registered address of Medicinova?
The registered address for Medicinova is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Medicinova website address?
The website address for Medicinova is www.medicinova.com
Which industry sector does Medicinova operate in?
Medicinova operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MGIHMillennium Group International Holdings Ltd
US$ 3,75
(145,10%)
12,98M
ZCARZoomcar Holdings Inc
US$ 3,42
(139,16%)
8,19M
ADDColor Star Technology Company Ltd
US$ 4,10
(89,81%)
5,09M
AIREreAlpha Tech Corporation
US$ 2,27
(65,69%)
12,33M
UPCUniverse Pharmaceuticals Inc
US$ 0,9899
(56,18%)
702,19k
NEUPNeuphoria Therapeutics Inc
 3,87
(-41,63%)
59,04k
HOURHour Loop Inc
US$ 2,83
(-35,68%)
302,33k
DRCTDirect Digital Holdings Inc
US$ 2,52
(-32,08%)
318,97k
BAOSBaosheng Media Group Holdings Ltd
US$ 5,01
(-29,44%)
102,51k
CREVCarbon Revolution Public Ltd
US$ 6,84
(-25,33%)
44,87k
LICNLichen China Limited
US$ 0,2768
(31,75%)
19,89M
MGIHMillennium Group International Holdings Ltd
US$ 3,75
(145,10%)
12,98M
AIREreAlpha Tech Corporation
US$ 2,27
(65,69%)
12,33M
ZCARZoomcar Holdings Inc
US$ 3,42
(139,16%)
8,19M
KWEKWESST Micro Systems Inc
US$ 0,6657
(19,56%)
6,29M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
MNOV
Medicinova
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés